Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Open Label, Phase 3 Trial Of Erlotinib Alone Or In Combination With CP-751,871 In Patients With Advanced Non Small Cell Lung Cancer Of Non Adenocarcinoma Histology

NCT00673049 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00673049
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00673049 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Open Label, Phase 3 Trial Of Erlotinib Alone Or In Combination With CP-751,871 In Patients With Advanced Non Small Cell Lung Cancer Of Non Adenocarcinoma Histology
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Terminated
Start date
May 31, 2008
Completion date
April 30, 2012
Enrollment
583 (actual)
Sites
175

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, adenosquamous cell, carcinoma, large cell, carcinoma, non-small-cell lung, carcinoma, squamous cell